Stents

Last week was all about fourth quarter results, debate over generic drugs and drug price control measures.

Drug pricing regulator rejects Abbott, Medtronic requests to withdraw stents

National Pharmaceutical Pricing Authority said on Wednesday said that the companies cannot pull their stents from the market abruptly after the duo had cited commercial viability concerns in their withdrawal applications.

Complaints against 30 hospitals for stent overcharging: NPPA

Regulator NPPA today said it has received complaints against 30 hospitals for overcharging on stents while some patients have received refunds for the excess payments.

Put price cap on medicines, hip & knee implants: Doctors to PM

Hailing the Centre's decision to put a cap on prices of coronary stents, a group of doctors today sought a similar cap on the prices of medicines, hip and knee implants and intraocular lenses.

Stents pricing: Govt asks hospitals to make prompt refunds

No action will be taken against hospitals under the scanner for overcharging on stents if they refund the money to patients before receiving a demand notice, drug price regulator NPPA said.

NPPA asks hospitals to display revised price list of stents

Regulator NPPA today asked hospitals to prominently display revised price list of stents while ordering manufacturers and importers to report to it in case of withdrawal or non-availability of products.

NPPA simplifies rules to ensure no stents shortage to patients

NPPA said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with its price cap order - a move seen as an attempt to simplify the process ensure continuation of cardiac services to patients.

After pricing cap, NPPA warns of 'artificial' shortage of stents

NPPA said the government can direct any manufacturer to maintain, import or increase supplies of cardiac stents in public interest, and a designated officer of government of both State and Central can enter, search and seize stocks of stents anywhere in the trade channel – if they found to be hoarding them.

NPPA's price caps on stents may hurt manufacturers: Medanta

The National Pharmaceutical Pricing Authority‘s new policy on stent is welcome as it improves access and brings in transparency, but capping coronary stent prices may hurt manufacturers, according to Medanta Chairman Naresh Trehan.

Expensive, newer stents not better for all: study

Many heart patients get newer, pricey stents inserted during artery-clearing procedures, even if it's not clear they would be worse off with more basic, less expensive stents, a new study suggests.